Scroll to Top

Stocks That Plunged: Immunomedics, Inc., (NASDAQ:IMMU); Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB); Repros Therapeutics Inc (NASDAQ:RPRX)

Posted in Health7 months ago • Written by Jenny LambNo Comments

Dallas, Texas, 09/29/2014 (ustrademedia) – On September 26, 2014 drug maker Immunomedics, Inc., (NASDAQ:IMMU) which is headquartered in MORRIS PLAINS, New Jersey has announced the release of a research report which documents the development of an “bi-specific antibody” by the drug maker’s research team. The antibody is found to redirect human T cells which fight certain forms of cancer by the infusion of drug interferon-alpha (IFNα). The research paper layouts the details of the proprietary DOCK-AND-LOCK® technology used to arrive at the positive results from this exercise. The drug maker pointed out that the treatment procedure was found to be highly active, while not showcasing any collateral increase in secondary cytokines.

On September 26, 2014 drug maker Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) announced that European Medicines Agency established Committee for Medicinal Products for Human Use has provided a positive response on its application to market Lymphoseek® 250 Mg kit in European Union. The positive opinion by the committee is to be reviewed by the European Commission regulator over the next few days. While the committee findings have no mandatory binding on the future ruling of European Medicines Agency on the marketing approval, generally the recommendations are followed by European Medicines Agency.

Drug maker Repros Therapeutics Inc (NASDAQ:RPRX) announced on 26th September that its request for appointment to discuss new drug application Type B meeting with the U.S Food and Drug Administration is tentatively scheduled for the first half of November. The New drug application is expected to be filed by end of 2014 as per the drug makers press note. The drug candidate in question is Androxal(R) which is designed to treat patients who are suffering from “secondary hypogonadism” which leads to drop in testicular activity. On the back of the release of this new update, the stock posted a huge 17 percent increase in its stock price on the back of huge demand from the investor community.

TAGS: , , , , , , , ,

Leave A Response